Maryland Oncology Hematology, PA

Silver Spring, Maryland 20904

9 studies enrolling now · 25 studies all time

What they study most

Advanced Breast Cancer, Advanced Non-Small Cell Lung Cancer, Breast Cancer, Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Carcinoma, Transitional Cell, Early Breast Cancer, Endometrial Cancer, Esophageal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Cancer

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer — Recruiting now
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• MYLUNG Consortium Part 3: Observational Study — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — Recruiting now
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer — Recruiting now
• A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC — Running, not enrolling
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer — Running, not enrolling
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected — Stopped early
• MYLUNG Consortium Study Protocol 2 — Running, not enrolling
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• Palbociclib in Real World Practice — Completed
• Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) — Completed
• Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy — Stopped early
• The Circulating Cell-free Genome Atlas Study — Status unconfirmed
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) — Completed
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer — Stopped early
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer — Completed
• A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC — Completed